# Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

- Link: https://www.thailand-business-news.com/pr-news/telix-educational-webinar-neuro-oncology-portfolio-update-and-physician-perspectives-on-future-therapeutic-directions
- Published: 2026-06-23T04:37:00+07:00
- Author: PR Newswire

|   |

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ — Telix Pharmaceuticals
Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar 
exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma)
and how theranostics may help address these.

David N. Cade, MD, Telix Group Chief Medical Officer will provide a clinical update,
which will be followed by a fireside chat with Nelleke Tolboom, MD, Nuclear Medicine
physician and academic faculty member at UMC Utrecht (Netherlands) and Josef Pichler,
MD, Head of the Neuro-oncological Center at Kepler University Hospital Linz (Austria).

The presentation will be followed by Q&A with Dr. Cade and Richard Valeix, CEO, 
Telix Therapeutics.

**Webinar date and time:**

EDT: Monday, June 29, 2026, 5:00 p.m.

AEST: Tuesday, June 30, 2026, 7:00 a.m.

Participants can register for the webinar at the following link:
[https://s1.c-conf.com/diamondpass/10054826-mur5i9.html](https://s1.c-conf.com/diamondpass/10054826-mur5i9.html)

**About Telix Pharmaceuticals Limited **

Telix is a global biopharmaceutical company focused on the development and commercialization
of radiopharmaceuticals with the goal of addressing significant unmet medical need
in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with
international operations in the United States, United Kingdom, Brazil, Canada, Europe(
Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities
Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit [www.telixpharma.com](http://www.telixpharma.com/) for further information
about Telix, including details of the latest share price, ASX and U.S. Securities
and Exchange Commission (SEC) filings, investor and analyst presentations, news 
releases, event details and other publications that may be of interest. You can 
also follow Telix on [LinkedIn](https://www.linkedin.com/company/telixpharma/), 
[X](https://x.com/TelixPharma) and [Facebook](https://www.facebook.com/TelixPharma).

Legal Notices

_Cautionary Statement Regarding Forward-Looking Statements._

_You should read this announcement together with our risk factors, as disclosed 
in our most recently filed reports with the Australian Securities Exchange (ASX),
U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form
20-F filed with the SEC, or on our website._

_The information contained in this announcement is not intended to be an offer for
subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals
Limited (Telix) in any jurisdiction, including the United States. The information
and opinions contained in this announcement are subject to change without notification.
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking
to update or revise any information or opinions contained in this announcement, 
including any forward-looking statements (as referred to below), whether as a result
of new information, future developments, a change in expectations or assumptions,
or otherwise. No representation or warranty, express or implied, is made in relation
to the accuracy or completeness of the information contained or opinions expressed
in the course of this announcement._

_This announcement may contain forward-looking statements, including within the 
meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate
to anticipated future events, financial performance, plans, strategies or business
developments. Forward-looking statements can generally be identified by the use 
of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe","
outlook", "forecast" and "guidance", or the negative of these words or other similar
terms or expressions. Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to differ materially from any future results, levels
of activity, performance or achievements expressed or implied by these forward-looking
statements. Forward-looking statements are based on Telix’s good-faith assumptions
as to the financial, market, regulatory and other risks and considerations that 
exist and affect Telix’s business and operations in the future and there can be 
no assurance that any of the assumptions will prove to be correct. In the context
of Telix’s business, forward-looking statements may include, but are not limited
to, statements about: the initiation, timing, progress, completion and results of
Telix’s preclinical and clinical trials, and Telix’s research and development programs;
Telix’s ability to advance product candidates into, enroll and successfully complete,
clinical studies, including multi-national clinical trials; the timing or likelihood
of regulatory filings and approvals for Telix’s product candidates, manufacturing
activities and product marketing activities; Telix’s sales, marketing and distribution
and manufacturing capabilities and strategies; the commercialization of Telix’s 
product candidates, if or when they have been approved; Telix’s ability to obtain
an adequate supply of raw materials at reasonable costs for its products and product
candidates; estimates of Telix’s expenses, future revenues and capital requirements;
Telix’s financial performance; developments relating to Telix’s competitors and 
industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic
conditions on Telix’s business, including as a result of war or other geopolitical
conflicts; and the pricing and reimbursement of Telix’s product candidates, if and
after they have been approved. Telix’s actual results, performance or achievements
may be materially different from those which may be expressed or implied by such
statements, and the differences may be adverse. Accordingly, you should not place
undue reliance on these forward-looking statements._

_Trademarks and Trade Names. All trademarks and trade names referenced in this press
release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable,
the property of their respective owners. For convenience, trademarks and trade names
may appear without the ® or ™ symbols. Such omissions are not intended to indicate
any waiver of rights by Telix or the respective owners. Trademark registration status
may vary from country to country. Telix does not intend the use or display of any
third-party trademarks or trade names to imply any affiliation with, endorsement
by, or sponsorship from those third parties._

_©2026 Telix Pharmaceuticals Limited. All rights reserved._

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions ](http://www.prnasia.com/story/archive/4988809_AE88809_0?rand=184833)